{"preliminary_commentary":{"by_channel":{"youtube":5,"podcast":2,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06526793\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SOUNDTRACK-B","nct_id":"NCT06526793","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=soundtrack-b-nct06526793. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SOUNDTRACK-B","arms":[{"description":"In Module 1, the efficacy and safety of surovatamig at the RP2D will be evaluated in R/R FL. Surovatamig will be administered as intravenous infusion.","label":"Module 1: Surovatamig Monotherapy in Participants with Relapsed or Refractory Follicular Lymphoma","type":"EXPERIMENTAL"},{"description":"In Module 2, the efficacy and safety of surovatamig at the RP2D will be evaluated in R/R LBCL. Surovatamig will be administered as intravenous infusion.","label":"Module 2: Surovatamig Monotherapy in Participants with Relapsed or Refractory LBCL","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-10-21","type":"ESTIMATED"},"conditions":["B-cell Non-Hodgkin Lymphoma","Follicular Lymphoma (FL)","Large B-Cell Lymphoma (LBCL)"],"enrollment":{"count":270,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Surovatamig","otherNames":["AZD0486"],"type":"DRUG"}],"last_update":"2026-10-14","lead_sponsor":"AstraZeneca","official_title":"A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-04-21","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response rate (ORR) (central review)","timeFrame":"Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 12 months."}],"references":[],"start_date":{"date":"2024-11-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","url":"https://clinicaltrials.gov/study/NCT06526793"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/soundtrack-b-nct06526793"}